XOMA Announces Servier Has Initiated a new Study in Patients With a History of Acute Coronary Syndrome
BERKELEY, Calif., Nov. 29, 2012 (GLOBE NEWSWIRE) -- XOMA Corporation (XOMA) today announced its partner, Servier, has initiated the first Servier-sponsored proof-of-concept study in a cardiovascular indication. The study has opened for patient enrollment. The study is expected to enroll 45 patients who have experienced Acute Coronary Syndrome (ACS) in the past three to twelve months. The objective of this study is to evaluate the effect of subcutaneous administration of 30 mg gevokizumab as compared to placebo in reducing arterial wall inflammation in patients with marked atherosclerotic plaque inflammation. The primary endpoint Servier will be assessing is the change in the mean target to background ratio (TBR) of the radioactive tracer FDG assessed by PET/CT after three months of treatment. The study also will determine gevokizumab's effect on a number of cardiac and vascular biological blood biomarkers.
"Servier is recognized for its global cardiovascular franchise and is well positioned for developing gevokizumab in cardiovascular disease," stated John Varian, Chief Executive Officer of XOMA. "While Servier has world-wide rights and pays all gevokizumab development costs for cardiovascular indications, XOMA has the option to acquire the U.S. and Japanese rights in this therapeutic area. As Servier develops gevokizumab in cardiovascular indications, it could become significantly more valuable to XOMA."
"Servier is very committed to developing innovative treatments for cardiovascular diseases with clear unmet medical needs, such as the Acute Coronary Syndrome. The potential anti-inflammatory properties of gevokizumab may ultimately prove its clinical value in this disease. Servier is delighted by this new and important step in the clinical development of the drug," said Isabelle Tupinon-Mathieu, M.D., Head of Therapeutic Research and Development at Servier.